Daria V. Voronina

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet · 2021 · 1.8K citations · Full text

Vaccination, Vaccine Safety, Vaccinology +10

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova et al. · The Lancet · 2020 · 1.1K citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +7

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet Regional Health - Europe · 2021 · 71 citations · Full text

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern

I. A. FAVORSKAYA, Dmitry V. Shcheblyakov, I. B. Esmagambetov et al. · Frontiers in Immunology · 2022 · 35 citations · Full text

Heterodimeric Molecule, Single-domain Antibodies, Vaccine Target +12

Development of the covalent antibody-DNA conjugates technology for detection of IgE and IgM antibodies by immuno-PCR

Artem Maerle, Maria A. Simonova, V. D. Pivovarov et al. · PLoS ONE · 2019 · 29 citations · Full text

Engineering, Immunology, Molecular Biology +18